Mona Bafadhel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7177936/publications.pdf

Version: 2024-02-01

107 papers	6,413 citations	126708 33 h-index	69108 77 g-index
112 all docs	112 docs citations	112 times ranked	6224 citing authors

#	Article	IF	Citations
1	Acute Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 662-671.	2.5	847
2	Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 48-55.	2.5	499
3	Expression of the T Helper 17-Associated Cytokines IL-17A and IL-17F in Asthma and COPD. Chest, 2010, 138, 1140-1147.	0.4	331
4	Lung microbiome dynamics in COPD exacerbations. European Respiratory Journal, 2016, 47, 1082-1092.	3.1	330
5	Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 763-772.	5.2	301
6	Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respiratory Medicine,the, 2018, 6, 117-126.	5.2	298
7	Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respiratory Medicine,the, 2014, 2, 891-901.	5.2	248
8	Chronic obstructive pulmonary disease. Lancet, The, 2022, 399, 2227-2242.	6.3	228
9	Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet, The, 2021, 398, 843-855.	6.3	204
10	Elevated Sputum Interleukin-5 and Submucosal Eosinophilia in Obese Individuals with Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 657-663.	2.5	198
11	Benralizumab for the Prevention of COPD Exacerbations. New England Journal of Medicine, 2019, 381, 1023-1034.	13.9	180
12	Eosinophils in COPD: just another biomarker?. Lancet Respiratory Medicine,the, 2017, 5, 747-759.	5.2	160
13	Precision medicine in airway diseases: moving to clinical practice. European Respiratory Journal, 2017, 50, 1701655.	3.1	151
14	Procalcitonin and C-Reactive Protein in Hospitalized Adult Patients With Community-Acquired Pneumonia or Exacerbation of Asthma or COPD. Chest, 2011, 139, 1410-1418.	0.4	145
15	An expert consensus framework for asthma remission as a treatment goal. Journal of Allergy and Clinical Immunology, 2020, 145, 757-765.	1.5	144
16	Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. European Respiratory Journal, 2014, 44, 789-791.	3.1	141
17	Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. Chest, 2016, 150, 320-328.	0.4	125
18	Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. Journal of Allergy and Clinical Immunology, 2018, 141, 2027-2036.e12.	1.5	124

#	Article	IF	Citations
19	Biological clustering supports both â€œDutchâ€•and â€œBritishâ€•hypotheses of asthma and chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2015, 135, 63-72.e10.	1.5	111
20	Aspergillus fumigatus during stable state and exacerbations of COPD. European Respiratory Journal, 2014, 43, 64-71.	3.1	110
21	Inflammatory Endotypeâ€“associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1488-1502.	2.5	107
22	The Role of CT Scanning in Multidimensional Phenotyping of COPD. Chest, 2011, 140, 634-642.	0.4	96
23	Routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence. Medical Mycology, 2012, 50, 433-438.	0.3	94
24	Association Between Pathogens Detected Using Quantitative Polymerase Chain Reaction With Airway Inflammation in COPD at Stable State and Exacerbations. Chest, 2015, 147, 46-55.	0.4	74
25	Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax, 2021, 76, 188-195.	2.7	73
26	Blood eosinophil count and exacerbation risk in patients with COPD. European Respiratory Journal, 2017, 50, 1700761.	3.1	64
27	COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulmonary Medicine, 2014, 14, 112.	0.8	62
28	Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 660-671.	2.5	62
29	Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function. International Journal of COPD, 2015, 10, 1075.	0.9	61
30	Neutrophil elastase as a biomarker for bacterial infection in COPD. Respiratory Research, 2019, 20, 170.	1.4	53
31	Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?. Lancet Respiratory Medicine,the, 2020, 8, 846-847.	5.2	48
32	Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma. Mucosal Immunology, 2018, 11, 1408-1419.	2.7	46
33	Successful awake proning is associated with improved clinical outcomes in patients with COVID-19: single-centre high-dependency unit experience. BMJ Open Respiratory Research, 2020, 7, e000678.	1.2	44
34	Exhaled nitric oxide and blood eosinophilia: Independent markers of preventable risk. Journal of Allergy and Clinical Immunology, 2013, 132, 828-829.	1.5	34
35	Building toolkits for COPD exacerbations: lessons from the past and present. Thorax, 2019, 74, 898-905.	2.7	34
36	Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a Haemophilusâ€predominant subgroup. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 808-817.	2.7	33

#	Article	IF	Citations
37	Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. International Journal of COPD, 2021, Volume 16, 1755-1770.	0.9	30
38	Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis. Lancet Respiratory Medicine,the, 2022, 10, 545-556.	5.2	30
39	Research priorities for exacerbations of COPD. Lancet Respiratory Medicine,the, 2021, 9, 824-826.	5.2	28
40	A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials, 2020, 21, 718.	0.7	25
41	Microbiome balance in sputum determined by PCR stratifies COPD exacerbations and shows potential for selective use of antibiotics. PLoS ONE, 2017, 12, e0182833.	1.1	25
42	Exome-wide analysis of rare coding variation identifies novel associations with COPD and airflow limitation inMOCS3,IFIT3andSERPINA12. Thorax, 2016, 71, 501-509.	2.7	22
43	Infection, inflammation and intervention: mechanistic modelling of epithelial cells in COVID-19. Journal of the Royal Society Interface, 2021, 18, 20200950.	1.5	22
44	A Comprehensive Analysis of the Stability of Blood Eosinophil Levels. Annals of the American Thoracic Society, 2021, 18, 1978-1987.	1.5	19
45	Resistome analyses of sputum from COPD and healthy subjects reveals bacterial load-related prevalence of target genes. Thorax, 2020, 75, 8-16.	2.7	18
46	Standardisation of Clinical Assessment, Management and Follow-Up of Acute Hospitalised Exacerbation of COPD: A Europe-Wide Consensus. International Journal of COPD, 2021, Volume 16, 321-332.	0.9	18
47	Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. International Journal of COPD, 2021, Volume 16, 499-517.	0.9	17
48	Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis. Respiratory Research, 2020, 21, 17.	1.4	16
49	Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial. BMJ Open Respiratory Research, 2020, 7, e000577.	1.2	15
50	Investigating the role of pentraxin 3 as a biomarker for bacterial infection in subjects with COPD. International Journal of COPD, 2017, Volume 12, 1199-1205.	0.9	14
51	The Use of Benralizumab in the Treatment of Near-Fatal Asthma: A New Approach. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1441-1443.	2.5	14
52	Impaired P2X1 Receptorâ€“Mediated Adhesion in Eosinophils from Asthmatic Patients. Journal of Immunology, 2016, 196, 4877-4884.	0.4	13
53	Exacerbations of chronic obstructive pulmonary disease: time to rename. Lancet Respiratory Medicine,the, 2020, 8, 133-135.	5.2	13
54	Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. International Journal of COPD, 2014, 9, 179.	0.9	12

#	Article	IF	Citations
55	Systemic and pulmonary inflammation is independent of skeletal muscle changes in patients with chronic obstructive pulmonary disease. International Journal of COPD, 2014, 9, 975.	0.9	12
56	Eosinophils in COPD: are we nearly there yet?. Lancet Respiratory Medicine,the, 2017, 5, 913-914.	5.2	12
57	Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population. ERJ Open Research, 2022, 8, 00606-2021.	1.1	12
58	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. Annals of the American Thoracic Society, 2019, 16, 29-39.	1.5	11
59	The CICERO (Collaboration In COPD ExaceRbatiOns) Clinical Research Collaboration. European Respiratory Journal, 2020, 55, 2000079.	3.1	10
60	Predictive modeling of COPD exacerbation rates using baseline risk factors. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662211073.	1.0	10
61	Toll-like receptor 9 dependent interferon-Î± release is impaired in severe asthma but is not associated with exacerbation frequency. Immunobiology, 2015, 220, 859-864.	0.8	9
62	Comparison of the peripheral blood eosinophil count using near-patient testing and standard automated laboratory measurement in healthy, asthmatic and COPD subjects. International Journal of COPD, 2017, Volume 12, 2771-2775.	0.9	9
63	Discordant diagnostic criteria for pneumonia in COPD trials: a review. European Respiratory Review, 2021, 30, 210124.	3.0	8
64	Body Mass and Fat Mass in Refractory Asthma: An Observational 1 Year Follow-Up Study. Journal of Allergy, 2010, 2010, 1-9.	0.7	7
65	Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of COPD?: PRO. Medical Sciences (Basel, Switzerland), 2018, 6, 74.	1.3	7
66	Inhaled budesonide for early treatment of COVID-19 â€“ Authors' reply. Lancet Respiratory Medicine,the, 2021, 9, e61.	5.2	7
67	Are COPD and cardiovascular disease fundamentally intertwined?. European Respiratory Journal, 2016, 47, 1307-1309.	3.1	6
68	Antimicrobial Peptides SLPI and Beta Defensin-1 in Sputum are Negatively Correlated with FEV1. International Journal of COPD, 2021, Volume 16, 1437-1447.	0.9	6
69	Investigating blood eosinophil count thresholds in patients with COPD. Lancet Respiratory Medicine,the, 2018, 6, 823-824.	5.2	5
70	Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations. Respiratory Medicine, 2019, 154, 27-33.	1.3	4
71	A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. European Respiratory Journal, 2021, 58, 2004522.	3.1	4
72	Alternatives to induced sputum for identifying inflammatory subtypes of asthma. Respirology, 2017, 22, 624-625.	1.3	3

#	Article	IF	Citations
73	COPD exacerbations: transforming outcomes through research. Lancet Respiratory Medicine,the, 2018, 6, 172-174.	5.2	3
74	High serum G-CSF characterises neutrophilic COPD exacerbations associated with dysbiosis. ERJ Open Research, 2021, 7, 00836-2020.	1.1	3
75	Predicting treatment outcomes following an exacerbation of airways disease. PLoS ONE, 2021, 16, e0254425.	1.1	3
76	Fractional exhaled nitric oxide in chronic obstructive pulmonary disease. , 2015, , .		3
77	Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals. International Journal of COPD, 2021, Volume 16, 3009-3016.	0.9	3
78	Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant. BMJ Open Respiratory Research, 2021, 8, e001044.	1.2	3
79	Chronic obstructive pulmonary disease: management of chronic disease. Medicine, 2016, 44, 310-313.	0.2	2
80	Eosinophilic inflammation, coronavirus disease 2019, and asthma. Annals of Allergy, Asthma and Immunology, 2021, 127, 278.	0.5	2
81	Renaming COPD exacerbations: the UK respiratory nursing perspective. BMC Pulmonary Medicine, 2021, 21, 299.	0.8	2
82	Chronic Obstructive Pulmonary Disease Exacerbations: Do All Roads Lead to Rome?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1125-1126.	2.5	2
83	The Role Of A Peripheral Blood Eosinophil Count As A Biomarker For A Sputum Eosinophilia In COPD Exacerbations. , 2010, , .		1
84	Visual vs Automated Assessment of Emphysema: Response. Chest, 2011, 140, 1385.	0.4	1
85	Chronic obstructive pulmonary disease: management of chronic disease. Medicine, 2012, 40, 262-266.	0.2	1
86	Symptomatic COPD: is it time for triple therapy?. Lancet Respiratory Medicine,the, 2018, 6, 728-729.	5.2	1
87	Recruiting patients to a digital self-management study whilst in hospital for a chronic obstructive pulmonary disease exacerbation: A feasibility analysis. Digital Health, 2021, 7, 205520762110208.	0.9	1
88	Biomarkers in COPD. , 2021, , .		1
89	Ethnicity-based differences in asthma diagnostic thresholds. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1124.	2.0	1
90	The Risk Factors That Identify With Airflow Obstruction And Exacerbations In Severe Asthma. , 2010, , .		0

#	Article	IF	Citations
91	The Influence Of Body Mass Index Upon Emphysema In COPD. , 2010, , .		0
92	Procalcitonin vs Clinical and Chest Film Findings to Diagnose Community-Acquired Pneumonia in Patients With Acute Asthma or Acute Exacerbations of Chronic Bronchitis: Response. Chest, 2011, 140, 1668.	0.4	0
93	Serum Procalcitonin and Infective Exacerbations of Asthma: Response. Chest, 2011, 140, 1390-1391.	0.4	0
94	Genome-Wide Association Study Identifies Novel Loci Associated With Reversibility To Â²2 Agonist In Severe Asthma Subjects. , 2012, , .		0
95	Genome-Wide Association Study Identifies Novel Loci Associated With Forced Expiratory Volume In One Second (FEV1) As A Percent Of Predicted In Severe Asthma Subjects. , 2012, , .		0
96	Respimat vs HandiHaler: a lesson in asking the right question. The Prescriber, 2014, 25, 7-8.	0.1	0
97	Flu vaccine reduces risk of adverse CV events in high-risk patients. The Prescriber, 2014, 25, 34-34.	0.1	0
98	Is it time to give up on â€œself-managementâ€•of COPD exacerbations?. European Respiratory Journal, 2020, 55, 1902102.	3.1	0
99	Evaluating the sensitivity and specificity of NEATstik technology compared to an activity-based immunoassay in sputum samples from participants with COPD. European Respiratory Journal, 2020, 55, 1902412.	3.1	0
100	Detection of Cell-Dissociated Non-Typeable Haemophilus influenzae in the Airways of Patients with Chronic Obstructive Pulmonary Disease . International Journal of COPD, 2020, Volume 15, 1357-1365.	0.9	0
101	Eosinophilic Chronic Obstructive Pulmonary Disease is Not Associated with Helminth Infection or Exposure. Journal of Pulmonary & Respiratory Medicine, 2014, 04, .	0.1	0
102	Investigation the role of pentraxin-3 in the innate immune system in patients with COPD. , 2015, , .		0
103	The identification of distinct immunophenotypical subgroups in a COPD patient population based on predominating T-lymphocyte subsets. , 2015, , .		0
104	The detection of free-living H. influenzae in the airways of patients with COPD. , 2015, , .		0
105	What will Happen in the World of COPD 2030?. Turkish Thoracic Journal, 2019, 20, 153-257.	0.2	0
106	Heterogeneity of IPF exacerbations. Lancet Respiratory Medicine,the, 2022, 10, e3.	5.2	0
107	High-dose budesonide for early COVID-19 â€“ Authors' reply. Lancet, The, 2021, 398, 2147-2148.	6.3	0